Stockscreener 앱 받기
8.78
1.57%
-0.14
전일 마감가:
$8.92
열려 있는:
$8.9
하루 거래량:
772.43K
Relative Volume:
0.71
시가총액:
$1.38B
수익:
$61.10M
순이익/손실:
$-138.36M
주가수익비율:
-7.3167
EPS:
-1.2
순현금흐름:
$-90.59M
1주 성능:
-17.17%
1개월 성능:
-22.51%
6개월 성능:
+39.59%
1년 성능:
+273.62%
1일 변동 폭
$8.57
$8.9853
1주일 범위
$8.5101
$10.73
52주 변동 폭
$2.145
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
15 CROSBY DRIVE, BEDFORD, MA
OCUL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| OCUL | 8.78 | 1.38B | 61.10M | -138.36M | -90.59M | -1.20 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates - MSN
Ocular Therapeutix Q3 2024 Earnings Preview - MSN
(OCUL) Technical Data - Stock Traders Daily
Ocular Therapeutix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
GSA Capital Partners LLP Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Given New $15.00 Price Target at HC Wainwright - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2024 Earnings Call Transcript - Insider Monkey
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance
Ocular Therapeutix Posts Mixed Third Quarter 2024 Results - Vision Monday
Ocular Therapeutix: Q3 Earnings Snapshot - Houston Chronicle
Ocular Therapeutix Reports Q3 2024 Financial Results - TipRanks
Ocular Therapeutix Inc. (OCUL) Quarterly 10-Q Report - Quartzy
Avoro Capital Advisors LLC Acquires Significant Stake in Ocular Therapeutix Inc - GuruFocus.com
Ocular Therapeutix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ocular Therapeutix Inc earnings beat by $0.02, revenue fell short of estimates - Investing.com
Ocular Therapeutix Inc Reports Q3 2024 Earnings: Revenue at $15. - GuruFocus.com
Q3 2024 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus.com
Ocular Therapeutix appoints Namrata Saroj as CBO - The Pharma Letter
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights - The Manila Times
Ocular Therapeutix Inc. Appoints Namrata Saroj, OD, as Chief Business Officer - Vision Monday
A Peek at Ocular Therapeutix's Future Earnings - Benzinga
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV - The Manila Times
What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnin - GuruFocus.com
Ocular Therapeutix™ to Present at the Jefferies London - GlobeNewswire
What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings - Yahoo Finance
Ocular Therapeutix appoints new Chief Business Officer By Investing.com - Investing.com Canada
Ocular Therapeutix appoints new Chief Business Officer - Investing.com
Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer - The Manila Times
Ocular Therapeutix (OCUL) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024 - GlobeNewswire
Rosalind Advisors Inc. Grows Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Vanguard Group Inc's Strategic Reduction in Ocular Therapeutix I - GuruFocus.com
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix stock soars to 52-week high of $11.64 By Investing.com - Investing.com South Africa
Ocular Therapeutix (NASDAQ:OCUL) Reaches New 1-Year HighHere's What Happened - MarketBeat
Ocular Therapeutix stock soars to 52-week high of $11.64 - Investing.com India
Short Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Drops By 18.1% - MarketBeat
Assenagon Asset Management S.A. Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, - openPR
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, Clinical Trials, Therapies, and Key Companies Involved by DelveInsight | Ocular Therapeutix, Aldeyra Therapeutics, Aciex Therapeutics - Barchart
Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? - MSN
HC Wainwright Reaffirms “Buy” Rating for Ocular Therapeutix (NASDAQ:OCUL) - Defense World
SG Americas Securities LLC Purchases Shares of 45,187 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Sets New 52-Week HighTime to Buy? - MarketBeat
Ocular Therapeutix stock soars to 52-week high of $11.34 - Investing.com
Ocular Therapeutix stock soars to 52-week high of $11.34 By Investing.com - Investing.com UK
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load? - Simply Wall St
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.69%
6.90%
자본화:
|
볼륨(24시간):